Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

A Phase II Study of AL-37807 to Treat Open-Angle Glaucoma or Ocular Hypertension

This study has been completed.
Information provided by:
Alcon Research Identifier:
First received: September 6, 2006
Last updated: April 21, 2008
Last verified: April 2008

The purpose of this study is to determine whether AL-37807 is safe and effective in treating patients with open-angle glaucoma or ocular hypertension

Condition Intervention Phase
Open-Angle Glaucoma
Ocular Hypertension
Drug: AL-37807
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: A Phase II Study of AL-37807 to Treat Open-Angle Glaucoma or Ocular Hypertension

Resource links provided by NLM:

Further study details as provided by Alcon Research:

Primary Outcome Measures:
  • Mean IOP change from baseline

Estimated Enrollment: 120
Study Start Date: May 2006
Primary Completion Date: August 2007 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Adult patients of either sex and any race with open-angle glaucoma or ocular hypertension; logMAR visual acuity not worse than 0.60; additionally clinically relevant ophthalmic or systemic conditions may be excluded

Exclusion Criteria:

  • Under 18
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00372931

United States, Texas
San Antonio Site
San Antonio, Texas, United States, 78240
Sponsors and Collaborators
Alcon Research
Study Director: Theresa Landry Study Director
  More Information

No publications provided Identifier: NCT00372931     History of Changes
Other Study ID Numbers: C-06-15
Study First Received: September 6, 2006
Last Updated: April 21, 2008
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Glaucoma, Open-Angle
Ocular Hypertension
Cardiovascular Diseases
Eye Diseases
Vascular Diseases processed this record on March 02, 2015